Ginkgo Bioworks Holdings, Inc. Class A Common Stock

Share · US37611X1000 · DNA (XNYS)

Overview

AI-Powered Analysis

Fundamental Analysis

Find out what the numbers really say — before the market does

Analyze now

News Sentiment

Are today's headlines a buy signal or a red flag?

Analyze now

Buy / Hold / Sell

Should you Buy, Hold, or Sell? Get the AI verdict now.

Analyze now

Risk Assessment

Uncover hidden risks before they hit your portfolio.

Analyze now

Fair Value

Is this stock cheap, fairly priced, or overvalued?

Analyze now

Latest AI Analyses of Ginkgo Bioworks Holdings, Inc. Class A Common Stock

Analyst Grade Summary

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

No Price

29.04.2026 15:31

Current Prices from Ginkgo Bioworks Holdings, Inc. Class A Common Stock

Exchange	Ticker	Currency	Last Trade	Price	Daily Change
IEX	DNA	USD	29.04.2026 15:31	7,43 USD	-0,42 USD -5,35 %
NYSE	DNA	USD	29.04.2026 15:30	7,44 USD	-0,41 USD -5,22 %

ESG Risk Rating

B Good

Share Float & Liquidity

Free Float 66,44 %

Shares Float 41,14 M

Shares Outstanding 61,92 M

Company Profile for Ginkgo Bioworks Holdings, Inc. Class A Common Stock Share

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.